IBRX - מכפיל P/S ImmunityBio Corp

ImmunityBio, Inc. (IBRX) possesses significant pricing power due to the inelastic demand for its unique NK therapy, while minimizing risks through diversification into infection treatments. The price/sales multiple helps balance these factors, where the value of 35.20 indicates the state of the parameter. Patent protection and the launch of an innovative bladder drug create a durable economic moat for the company.

The P/S ratio determines the market value of a business relative to its annual revenue, allowing an investor to assess the premium paid per unit of sales. By analyzing this price-to-sales ratio, one can see how the capitalization of ImmunityBio, Inc. (IBRX) reacts to clinical test results, as the inelastic demand for oncology drugs makes the company resilient to macroeconomic cycles and recessions.